Related Experiment Video
Updated: Jul 7, 2026

Design of a Biocompatible Drug-Eluting Tracheal Stent in Mice with Laryngotracheal Stenosis
Published on: January 21, 2020
GLP-1 Receptor Agonist Effect on Disease Severity in Idiopathic Subglottic Stenosis
Ronit E Malka1, Sam Collins1, Vasiliki Triantafillou1
1Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins Hospital, Baltimore, Maryland, USA.
Objective:
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have been associated with systemic anti-inflammatory effects in addition to weight loss. Their effect on idiopathic subglottic stenosis (iSGS) has not been evaluated. This study aimed to characterize the effect of GLP-1RAs on surgery-free interval (SFI) in iSGS.
Study Design:
Retrospective cohort study.
Setting:
Single-institution academic center.
Methods:
Two hundred and twenty-three iSGS patients were reviewed for GLP-1RA usage. SFI, and secondary measures of weight loss, body mass index (BMI), and Cotton-Myer grade before and after starting GLP-1RAs were analyzed. Patients were excluded if GLP-1RAs were begun prior to establishing SFI, or if serial intralesional steroid injection or endoscopic or open cricotracheal resection were performed. Statistical comparisons for SFI and weight loss were performed with paired t tests, univariate, and multiple linear regression, and a generalized linear mixed-effects model was used to compare Cotton-Myer grades, with a threshold for significance of α = .05.
Results:
Thirty-two patients (14%) were taking GLP-1RAs, with 14 meeting the inclusion criteria. SFI increased by a mean of 10.7 months, or 68.5% (P = .001). Patients lost 39 pounds on average, with a mean BMI decrement of 6.8 points (P < .001). There was no appreciable correlation between weight loss, initial BMI, and SFI on multiple linear regression (P = .92, adjusted R2 = -0.16) or univariate linear regression between SFI and weight loss (P = .98, R2 < 0.001) or BMI (P = .72, R2 = 0.01). There was no difference in Cotton-Myer grade at the time of surgery between patients before and after starting therapy (P = .44).
Conclusion:
GLP-1RA therapy increases SFI in iSGS independent of initial BMI or weight loss.
Level Of Evidence:
IV.
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
GPCRs Regulate Adenylyl Cylase Activity
Two...
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Esophageal Strictures-II: Clinical Features and Management
Healthcare providers should gather a comprehensive medical history and conduct a physical examination for diagnosis. If esophageal stricture is...
Esophageal Achalasia
